Bartakova Alena, Alvarez-Delfin Karen, Weisman Alejandra D, Salero Enrique, Raffa Gabriella A, Merkhofer Richard M, Kunzevitzky Noelia J, Goldberg Jeffrey L
Shiley Eye Institute, University of California San Diego, La Jolla, California, United States.
Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2749-62. doi: 10.1167/iovs.15-18826.
Human corneal endothelial cell (HCEC) density decreases with age, surgical complications, or disease, leading to vision impairment. Such endothelial dysfunction is an indication for corneal transplantation, although there is a worldwide shortage of transplant-grade tissue. To overcome the current poor donor availability, here we isolate, expand, and characterize HCECs in vitro as a step toward cell therapy.
Human corneal endothelial cells were isolated from cadaveric corneas and expanded in vitro. Cell identity was evaluated based on morphology and immunocytochemistry, and gene expression analysis and flow cytometry were used to identify novel HCEC-specific markers. The functional ability of HCEC to form barriers was assessed by transendothelial electrical resistance (TEER) assays.
Cultured HCECs demonstrated canonical morphology for up to four passages and later underwent endothelial-to-mesenchymal transition (EnMT). Quality of donor tissue influenced cell measures in culture including proliferation rate. Cultured HCECs expressed identity markers, and microarray analysis revealed novel endothelial-specific markers that were validated by flow cytometry. Finally, canonical HCECs expressed higher levels of CD56, which correlated with higher TEER than fibroblastic HCECs.
In vitro expansion of HCECs from cadaveric donor corneas yields functional cells identifiable by morphology and a panel of novel markers. Markers described correlated with function in culture, suggesting a basis for cell therapy for corneal endothelial dysfunction.
人角膜内皮细胞(HCEC)密度会随着年龄增长、手术并发症或疾病而降低,进而导致视力受损。尽管全球范围内移植级组织短缺,但这种内皮功能障碍仍是角膜移植的指征。为克服当前供体可用性差的问题,我们在此分离、扩增并鉴定体外培养的HCEC,作为细胞治疗的第一步。
从尸体角膜中分离出人角膜内皮细胞并在体外进行扩增。基于细胞形态和免疫细胞化学评估细胞特性,利用基因表达分析和流式细胞术鉴定新的HCEC特异性标志物。通过跨内皮电阻(TEER)测定评估HCEC形成屏障的功能能力。
培养的HCEC在传代至四代时呈现典型形态,随后经历内皮-间充质转化(EnMT)。供体组织质量影响培养中的细胞指标,包括增殖率。培养的HCEC表达特征性标志物,微阵列分析揭示了新的内皮特异性标志物,并通过流式细胞术进行了验证。最后,典型的HCEC表达较高水平的CD56,与成纤维细胞样HCEC相比,其TEER更高。
从尸体供体角膜体外扩增HCEC可产生通过形态和一组新标志物鉴定的功能性细胞。所述标志物与培养中的功能相关,为角膜内皮功能障碍的细胞治疗提供了基础。